Dupilumab In Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-seVere Eczema tRial
Status:
Not yet recruiting
Trial end date:
2025-07-23
Target enrollment:
Participant gender:
Summary
The primary objective of the study is:
• To describe further the efficacy of dupilumab on extent and severity of eczematous lesions
in skin of color participants, at least (≥)12 years old, with moderate-to-severe atopic
dermatitis (AD)
The secondary objectives of the study are:
- To describe further the efficacy of dupilumab on pruritus and other AD symptoms in skin
of color participants, ≥12 years old, with moderate-to-severe AD
- To describe further the efficacy of dupilumab on measures of mental health (anxiety and
depression) and quality of life (QOL) in skin of color participants, ≥12 years old, with
moderate-to-severe AD
- To describe further the safety of dupilumab administered to skin of color participants,
≥12 years old, with moderate-to-severe AD
- To assess dupilumab modulation of type 2 biomarkers in skin of color participants, ≥12
years old, with moderate-to-severe AD
- To evaluate further the systemic exposure of dupilumab in skin of color participants,
≥12 years old, with moderate-to-severe AD